Navelbine (Vinorelbine Tartrate)

Vinorelbine is used in oncology to target rapidly dividing cancer cells in specific tumour types.

• Non‑small cell lung cancer: improves disease control and extends survival when used in combination chemotherapy.
• Breast cancer: contributes to tumour reduction and progression delay in metastatic or advanced disease.
• Metastatic breast cancer: administered as part of multi‑agent regimens to enhance overall response rates.

• Vinorelbine binds to tubulin at the vinca binding site, preventing microtubule assembly and thereby inhibiting mitotic spindle formation. This blockade arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly proliferating cancer cells. The drug’s activity is independent of DNA synthesis and primarily affects cells undergoing division.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Anemia: decreased red blood cells causing fatigue.
• Nausea: sensation of urge to vomit.
• Vomiting: expulsion of stomach contents.
• Constipation: difficulty passing stools.
• Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Pulmonary toxicity: inflammation or fibrosis of lung tissue.
• Peripheral neuropathy: tingling or numbness in extremities.
• Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: arrhythmias or reduced cardiac function.

When using Vinorelbine, clinicians should observe several safety measures to minimise risk.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: evaluate hepatic enzymes before and during therapy.
• Evaluate neuropathy: avoid in patients with pre‑existing peripheral nerve disorders.
• Avoid concurrent myelosuppressive agents: limit additive bone‑marrow toxicity.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels.
• Concurrent myelosuppressive chemotherapy: heighten risk of severe bone‑marrow suppression.
• Other vinca alkaloids: additive neurotoxicity.
• Monoclonal antibodies affecting bone marrow (e.g., bevacizumab): increase hematologic toxicity.

Moderate Interactions (Monitor Closely)

• Antiemetics such as ondansetron: may affect QT interval.
• Anticoagulants (warfarin): monitor INR for bleeding risk.
• CYP3A4 substrate drugs (e.g., midazolam): possible altered metabolism.
• Diuretics: watch electrolyte balance.
• NSAIDs: increased risk of gastrointestinal bleeding.